Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


Molecular responses to immune checkpoint blockade in glioblastoma

Transcriptional signatures and immune cell infiltrates associated with immune activation distinguish patients with glioblastoma who initially respond to immune checkpoint blockade from those who do not.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The molecular responses of GBM to checkpoint blockade.


  1. Ostrom, Q. T. et al. Neuro. Oncol. 20, iv1–iv86 (2018).

    Article  Google Scholar 

  2. Nam, J. Y. & de Groot, J. F. J. Oncol. Pract. 13, 629–638 (2017).

    Article  Google Scholar 

  3. Chiocca, E. A., Nassiri, F., Wang, J., Peruzzi, P. & Zadeh, G. Neuro. Oncol. 21, 14–25 (2019).

    Article  Google Scholar 

  4. Kamiya-Matsuoka, C. & Gilbert, M. R. CNS Oncol. 4, 91–104 (2015).

    Article  CAS  Google Scholar 

  5. Dyck, L. & Mills, K. H. G. Eur. J. Immunol. 47, 765–779 (2017).

    Article  CAS  Google Scholar 

  6. Zhao, J. Nat. Med. (2019).

  7. Mooney, K. L. et al. J. Clin. Neurosci. 34, 1–5 (2016).

    Article  CAS  Google Scholar 

  8. Schalper, K. A. Nat. Med. (2019).

  9. Cloughsey, T. F. Nat. Med. (2019).

  10. Hegi, M. E. et al. N. Engl. J. Med. 352, 997–1003 (2005).

    Article  CAS  Google Scholar 

  11. Yan, H. et al. N. Engl. J. Med. 360, 765–773 (2009).

    Article  CAS  Google Scholar 

  12. Keskin, D. B. et al. Nature 565, 234–239 (2019).

    Article  Google Scholar 

  13. Kurz, S. C. & Wen, P. Y. Curr. Treat. Options Neurol. 20, 14 (2018).

    Article  Google Scholar 

  14. Thomas, A. A. et al. Cancer Immunol. Immunother. 66, 379–389 (2017).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to E. Antonio Chiocca.

Ethics declarations

Competing interests

E.A.C is currently an advisor to Advantagene Inc., Alcyone Biosciences, Insightec, Inc., Sigilon Therepeutics and DNAtrix Inc. and has equity interest in DNAtrix; he has also advised Oncorus, Merck, Tocagen, Ziopharm, Stemgen, NanoTx., Ziopharm Oncology, Cerebral Therapeutics, Genenta, Merck, Janssen, Karcinolysis, and Shanaghai Biotech. He has received research support from the National Institutes of Health, the US Department of Defense, American Brain Tumor Association, National Brain Tumor Society, Alliance for Cancer Gene Therapy, Neurosurgical Research Education Foundation, Advantagene, NewLink Genetics, and Amgen. He also is a named inventor on patents related to oncolytic HSV1.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ito, H., Nakashima, H. & Chiocca, E.A. Molecular responses to immune checkpoint blockade in glioblastoma. Nat Med 25, 359–361 (2019).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing